ABSTRACT
Background Sleep Disordered Breathing (SDB) is characterized by repeated breathing reductions or cessations during sleep, often accompanied by oxyhemoglobin desaturation. How SDB affects the molecular environment is still poorly understood.
Methods We studied the association of three SDB measures: the Apnea Hypopnea Index (AHI), average and minimum oxyhemoglobin saturation during sleep (AvgO2 and MinO2) with gene expression measured using RNA-seq in peripheral blood mononuclear cells (PBMCs), monocytes, and T-cells, in ∼500 individuals from the Multi-Ethnic Study of Atherosclerosis (MESA). We developed genetic instrumental variables (IVs) for the associated transcripts as polygenic risk scores (tPRS), then generalized and validated the tPRS in the Women’s Health Initiative (WHI). Next, we constructed the tPRS and studied their association with SDB measures (to identify potential reverse causal associations) and with serum metabolites (to identify downstream effects) in ∼12,000 and ∼4,000 participants, respectively, from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Finally, we estimated the association of these SDB measures with transcript IV-associated metabolites in HCHS/SOL, to verify complete association pathways linking SDB, gene expression, and metabolites.
Results Across the three leukocyte cell types, 96 gene transcripts were associated with at least one SDB exposure (False Discovery Rate (FDR) p-value <0.1). Across cell populations, estimated log-fold expression changes were similar between AHI and MinO2 (Spearman correlations>0.90), and less similar between AvgO2 and the other exposures. Eight and four associations had FDR p-value<0.05 when the analysis was not adjusted and adjusted to BMI, respectively. Associations include known genes that respond to (PDGFC) and regulate response to (AJUBA) hypoxia. We identified a complete “chain” linking AvgO2, P2RX4, and butyrylcarnitine (C4), suggesting that increased expression of the purinergic receptor P2RX4 may improve average oxyhemoglobin saturation and decrease butyrylcarnitine (C4) levels.
Conclusions Our results support a mechanistic role for purinergic signaling and hypoxic signaling, among others, in SDB. These findings show differential gene expression by blood cell type in relation to SDB traits and link P2XR4 expression to influencing AvgO2 and butyrylcarnitine (C4) levels. Overall, we employed novel methods for integrating multi-omic data to evaluate biological mechanisms underlying multiple SDB traits.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Heart Lung and Blood Institute grants R35HL135818 to S.R., T32-HL007901 to D.C-T., and R21HL145425 to T.S. Molecular data for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung and Blood Institute (NHLBI). Genome Sequencing for NHLBI TOPMed: Multi-Ethnic Study of Atherosclerosis (MESA) (phs001416.v1.p1) was performed at the Broad Institute Genomics Platform (HHSN268201500014C). RNA-Seq for NHLBI TOPMed: Multi-Ethnic Study of Atherosclerosis (MESA) (phs001416.v1.p1) was performed at the Northwest Genomics Center (HHSN268201600032I). Genome Sequencing for NHLBI TOPMed: Women's Health Inititative (WHI) (phs001237.v3.p1) was performed at the Broad Institute Genomics Platform (HHSN268201500014C). RNA-Seq for NHLBI TOPMed: Women's Health Inititative (WHI) (phs001237.v3.p1) was performed at the Broad Institute Genomics Platform (HHSN268201600034I). Core support including centralized genomic read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Core support including phenotype harmonization, data management, sample-identity QC, and general program coordination were provided by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001I). The MESA projects are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for the Multi-Ethnic Study of Atherosclerosis (MESA) projects are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, UL1-TR-001420, UL1TR001881, DK063491, and R01HL105756. The authors thank the other investigators, the staff, and the participants of the MESA study for their valuable contributions. A fill list of participating MESA investigators and institutes can be found at http://www.mesa-nhlbi.org. The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts 75N92021D00001, 75N92021D00002, 75N92021D00003, 75N92021D00004, 75N92021D00005. The Hispanic Community Health Study/Study of Latinos is a collaborative study supported by contracts from the National Heart, Lung, and Blood Institute (NHLBI) to the University of North Carolina (HHSN268201300001I / N01-HC-65233), University of Miami (HHSN268201300004I / N01-HC-65234), Albert Einstein College of Medicine (HHSN268201300002I / N01-HC-65235), University of Illinois at Chicago (HHSN268201300003I / N01-HC-65236 Northwestern Univ), and San Diego State University (HHSN268201300005I / N01-HC-65237). The following Institutes/Centers/Offices have contributed to the HCHS/SOL through a transfer of funds to the NHLBI: National Institute on Minority Health and Health Disparities, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, NIH Institution-Office of Dietary Supplements. The Genetic Analysis Center at the University of Washington was supported by NHLBI and NIDCR contracts (HHSN268201300005C AM03 and MOD03). Support for metabolomics data was graciously provided by the JLH Foundation (Houston, Texas).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All MESA participants provided written informed consent, and the study was approved by the Institutional Review Boards at The Lundquist Institute (formerly Los Angeles BioMedical Research Institute) at Harbor-UCLA Medical Center, University of Washington, Wake Forest School of Medicine, Northwestern University, University of Minnesota, Columbia University, and Johns Hopkins University. All WHI participants provided informed consent and the study was approved by the IRB of the Fred Hutchinson Cancer Research Center. The HCHS/SOL was approved by the institutional review boards (IRBs) at each field center, where all participants gave written informed consent, and by the Non-Biomedical IRB at the University of North Carolina at Chapel Hill, to the HCHS/SOL Data Coordinating Center. All IRBs approving the study are: Non-Biomedical IRB at the University of North Carolina at Chapel Hill. Chapel Hill, NC; Einstein IRB at the Albert Einstein College of Medicine of Yeshiva University. Bronx, NY; IRB at Office for the Protection of Research Subjects (OPRS), University of Illinois at Chicago. Chicago, IL; Human Subject Research Office, University of Miami. Miami, FL; Institutional Review Board of San Diego State University, San Diego, CA
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
DATA AVAILABILITY STATEMENT MESA, HCHS/SOL and WHI data are available through application to dbGaP according to the study specific accessions. MESA phenotypes are available in: phs000209; WHI phenotypes: phs000200; and HCHS/SOL phenotypes: phs000810. HCHS/SOL genotyping data: phs000880. MESA and WHI RNA-seq data has been deposited and will become available through the TOP-Med according to the study specific accessions; MESA: phs001416 ; WHI: phs000972. HCHS/SOL metabolomics data are available via data use agreement with the HCHS/SOL Data Coordinating Center at the University of North Carolina at Chapel Hill, see collaborators website: https://sites.cscc.unc.edu/hchs/. Data needed to construct the tPRS are publicly available on the repository https://github.com/nkurniansyah/SDB_Multi_Omics.
